BioNTech SE (NASDAQ:BNTX) Receives Average Recommendation of "Moderate Buy" from Brokerages

Shares of BioNTech SE (NASDAQ:BNTX - Get Free Report) have received an average recommendation of "Moderate Buy" from the eighteen ratings firms that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $143.44.

Several analysts recently weighed in on the stock. Wells Fargo & Company assumed coverage on shares of BioNTech in a research report on Wednesday, December 11th. They issued an "overweight" rating and a $170.00 price objective on the stock. Truist Financial began coverage on BioNTech in a report on Friday, January 10th. They set a "buy" rating and a $172.00 price target on the stock. BMO Capital Markets boosted their price objective on BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 11th. Citigroup assumed coverage on BioNTech in a research report on Thursday, March 13th. They issued a "buy" rating and a $145.00 target price on the stock. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th.

BioNTech Stock Performance

BNTX stock traded down $3.96 during midday trading on Tuesday, reaching $88.05. The company had a trading volume of 1,035,719 shares, compared to its average volume of 843,634. The firm has a market capitalization of $21.13 billion, a PE ratio of -41.93 and a beta of 1.07. The stock has a 50 day moving average price of $108.81 and a 200 day moving average price of $112.80. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01.

Remove Ads

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings data on Monday, March 10th. The company reported $1.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion during the quarter, compared to analyst estimates of $1.24 billion. During the same quarter in the previous year, the firm posted $1.90 EPS. The business's revenue for the quarter was down 19.5% compared to the same quarter last year. Analysts anticipate that BioNTech will post -3.88 earnings per share for the current year.

Institutional Trading of BioNTech

Several institutional investors and hedge funds have recently added to or reduced their stakes in BNTX. Daiwa Securities Group Inc. increased its holdings in shares of BioNTech by 7.1% in the fourth quarter. Daiwa Securities Group Inc. now owns 1,938 shares of the company's stock valued at $221,000 after buying an additional 128 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in shares of BioNTech by 4.3% in the 4th quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after acquiring an additional 150 shares during the last quarter. Probity Advisors Inc. raised its position in shares of BioNTech by 8.5% during the fourth quarter. Probity Advisors Inc. now owns 1,970 shares of the company's stock worth $224,000 after purchasing an additional 154 shares during the period. Midwest Professional Planners LTD. lifted its holdings in shares of BioNTech by 5.8% during the fourth quarter. Midwest Professional Planners LTD. now owns 4,051 shares of the company's stock valued at $462,000 after purchasing an additional 222 shares during the last quarter. Finally, Perigon Wealth Management LLC boosted its position in shares of BioNTech by 3.9% in the 4th quarter. Perigon Wealth Management LLC now owns 5,902 shares of the company's stock valued at $666,000 after purchasing an additional 224 shares during the period. 15.52% of the stock is owned by institutional investors and hedge funds.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.